BE763735A - Forme pharmaceutique a effet retard et sa - Google Patents

Forme pharmaceutique a effet retard et sa

Info

Publication number
BE763735A
BE763735A BE763735A BE763735A BE763735A BE 763735 A BE763735 A BE 763735A BE 763735 A BE763735 A BE 763735A BE 763735 A BE763735 A BE 763735A BE 763735 A BE763735 A BE 763735A
Authority
BE
Belgium
Prior art keywords
pharmaceutical form
delayed pharmaceutical
delayed
pharmaceutical
Prior art date
Application number
BE763735A
Other languages
English (en)
French (fr)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of BE763735A publication Critical patent/BE763735A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
BE763735A 1970-03-05 1971-03-03 Forme pharmaceutique a effet retard et sa BE763735A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2010416A DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung

Publications (1)

Publication Number Publication Date
BE763735A true BE763735A (fr) 1971-09-03

Family

ID=5764197

Family Applications (1)

Application Number Title Priority Date Filing Date
BE763735A BE763735A (fr) 1970-03-05 1971-03-03 Forme pharmaceutique a effet retard et sa

Country Status (13)

Country Link
US (1) US3835221A (OSRAM)
JP (1) JPS5331930B1 (OSRAM)
AT (1) AT305498B (OSRAM)
BE (1) BE763735A (OSRAM)
CA (1) CA977680A (OSRAM)
DE (1) DE2010416B2 (OSRAM)
DK (1) DK132303C (OSRAM)
ES (1) ES388698A1 (OSRAM)
FR (1) FR2085672B1 (OSRAM)
GB (1) GB1326995A (OSRAM)
NL (1) NL169680C (OSRAM)
SE (1) SE377886B (OSRAM)
ZA (1) ZA711412B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296232A (en) * 1989-05-05 1994-03-22 Kv Pharmaceutical Company Pharmaceutical formulation which does not induce tolerance
US5445829A (en) * 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
FR2377196A1 (fr) * 1977-01-13 1978-08-11 Lipha Composition medicamenteuse a usage oral
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2397840B1 (OSRAM) * 1977-07-22 1981-03-20 Cherqui Jean
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
GB1584130A (en) * 1978-05-30 1981-02-04 Wyeth John & Brother Ltd Indole derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
JPS55129219A (en) * 1979-03-29 1980-10-06 Asahi Chem Ind Co Ltd Slow-releasing preparation
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
ATE34300T1 (de) * 1981-07-15 1988-06-15 Key Pharma Theophyllin mit verlaengerter abgabe.
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
EP0111560A4 (en) * 1982-06-14 1987-02-03 Key Pharma Sustained release aspirin.
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
DE3382392D1 (de) * 1982-07-09 1991-10-02 Key Pharma Dosierungsart zur dauerhaften verabreichung von chinidin.
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
EP0171457B1 (en) * 1984-08-17 1992-03-25 The Wellcome Foundation Limited Composition for the controlled discharge of an active ingredient, and its preparation
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB2159714B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition of sparingly soluble medicament and method for its preparation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1268710A (en) * 1984-11-06 1990-05-08 Nagin K. Patel Drug in bead form and process for preparing same
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
IL110035A0 (en) * 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
FR2766367B1 (fr) * 1997-07-22 2000-03-31 Plantes Et Medecines Granules homeopathiques et procede de fabrication
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
JP2004531467A (ja) 2000-11-28 2004-10-14 エフ　エム　シー　コーポレーション 可食性ｐｇａ被覆組成物
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
PL1919458T6 (pl) 2006-01-27 2017-10-31 Univ California Powlekane dojelitowo cysteamina, cystamina i ich pochodne
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
DK2276485T3 (da) 2008-04-24 2014-10-13 Bristol Myers Squibb Co Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
SI2665477T1 (sl) 2011-01-20 2016-02-29 Bionevia Pharmaceuticals Inc. Modificirano sproščanje epalrestata ali njegovega derivata in metode za uporabo le-teh
CA2851387A1 (en) 2011-11-22 2013-05-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
CA2874461C (en) 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
ES2846776T3 (es) 2014-12-24 2021-07-29 Principia Biopharma Inc Dosificación específica del sitio de un inhibidor de BTK
CN113149983B (zh) 2015-06-03 2024-03-29 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3316877B1 (en) 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
HK1256256A1 (zh) * 2015-12-08 2019-09-20 Ardea Biosciences, Inc. 包含urat1的有效抑制剂的药物组合物
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
IL294560A (en) 2020-01-20 2022-09-01 Genzyme Corp Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis
JP2023522623A (ja) 2020-04-17 2023-05-31 ジェンザイム・コーポレーション 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
EP4294427A1 (en) 2021-02-19 2023-12-27 DuPont Nutrition Biosciences ApS Compositions for gut health
EP4297734A1 (en) 2021-02-23 2024-01-03 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same
EP4547249A1 (en) 2022-06-30 2025-05-07 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
EP4573190A1 (en) 2022-08-16 2025-06-25 International N&H Denmark ApS Expression systems for phosphatases
EP4580605A1 (en) 2022-09-02 2025-07-09 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2024064653A1 (en) 2022-09-20 2024-03-28 Dupont Nutrition Biosciences Aps Variant anti-viral polypeptides
JP2025534632A (ja) 2022-10-11 2025-10-17 プリンシピア バイオファーマ インコーポレイテッド 多発性硬化症治療のためのチロシンキナーゼ阻害剤
WO2025064636A1 (en) 2023-09-20 2025-03-27 Danisco Us Inc. Composition comprising an atp degrading enzyme and uses thereof
WO2025080755A1 (en) 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410417A (en) * 1944-03-04 1946-11-05 Lever Brothers Ltd Vitamin and mineral dietary supplement and method of making
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
FR1017117A (fr) * 1950-05-04 1952-12-02 Trialgol Lab Procédé de conditionnement à l'état de poudre de substances destinées à l'ingestion et produits en résultant
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2852433A (en) * 1956-03-07 1958-09-16 Eastman Kodak Co Method of making enteric medicament compositions
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
DE1228757B (de) * 1962-06-28 1966-11-17 Haessle Ab Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
DE1216486B (de) * 1964-04-23 1966-05-12 Merck Ag E Verfahren zur Herstellung von Dragees
US3365365A (en) * 1965-08-09 1968-01-23 Hoffmann La Roche Repeat action pharmaceutical compositions in the form of discrete beadlets
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296232A (en) * 1989-05-05 1994-03-22 Kv Pharmaceutical Company Pharmaceutical formulation which does not induce tolerance
US5445829A (en) * 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations

Also Published As

Publication number Publication date
DE2010416A1 (de) 1971-09-16
DK132303C (da) 1976-04-26
CA977680A (en) 1975-11-11
NL169680B (nl) 1982-03-16
US3835221A (en) 1974-09-10
AT305498B (de) 1973-02-26
ZA711412B (en) 1971-11-24
JPS5331930B1 (OSRAM) 1978-09-05
NL169680C (nl) 1982-08-16
DK132303B (da) 1975-11-24
ES388698A1 (es) 1974-02-16
NL7102590A (OSRAM) 1971-09-07
FR2085672A1 (OSRAM) 1971-12-31
SE377886B (OSRAM) 1975-08-04
DE2010416B2 (de) 1979-03-29
FR2085672B1 (OSRAM) 1974-04-12
GB1326995A (en) 1973-08-15

Similar Documents

Publication Publication Date Title
BE763735A (fr) Forme pharmaceutique a effet retard et sa
BE754242A (fr) Diamino-s-triazines et dinitro-s-triazines
BR7100643D0 (pt) Novo acondicionamento para medicamentos
BE761729A (fr) Capsule blocable
BE768269A (fr) Composition pharmaceutique
BE775640A (fr) Composition pharmaceutique
AT320135B (de) Zusammendrückbare Folienkapsel
BE787973A (fr) Comprimes pharmaceutiques a effet retard
FI53863B (fi) Stamavloppscentral foer avledning av spillvatten fraon en sanitaer anlaeggning
BE764768A (fr) Compositions pharmaceutiques
PH10599A (en) Fluorene-2-acetic acids and derivatives thereof
PH9962A (en) Novel indolylacetic acid derivatives and salts thereof
PH9959A (en) 1-phenoxy-2-hydroxy-3-hydroxyalkylamino-propanes and salts thereof
IT943626B (it) Sostanze profomate
BE770399A (fr) Composition pharmaceutique
BE763149R (fr) Benzamidoisoquinoleines et tetrahydro- et
IL35942A0 (en) Substituted 2-(5-nitro-2-thienyl)-quinazolines and their preparation
BE772487A (fr) Compositions pharmaceutiques
BE797211A (fr) Dichloro-thiazolothiazole et sa preparation
BE772024A (fr) Pigment monoazoique et sa preparation
BE799805A (fr) Nouvel agent immunosuppresseur et sa preparation
BE770403A (fr) Preparation pharmaceutique
BE777777A (fr) Nouvel antibiotique et sa preparation
MY7700251A (en) Amino-and acylamino-pyridine and hydropyridine derivatives
BE765430A (fr) Nouvel epoxy-bufadienolide a activite cardiotrope et sa preparation